Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.51 USD
Change Today +0.03 / 0.22%
Volume 109.6K
PETX On Other Exchanges
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - $20.63
52 Week Low
10/2/14 - $9.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio includes approximately 18 therapeutic candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the osteoarthritis pain in dogs, and degenerative joint disease in cats; AT-002, a ghrelin agonist for stimulation of appetite in dogs, as well as for weight gain in cats and dogs; AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs; AT-004, a monoclonal antibody (MAB) used in the treatment of B-cell lymphoma in dogs; and AT-005, a caninized MAB for the treatment of T-cell lymphoma in dogs. It also develops other products, such as AT-006 for treatment of ocular lesions caused by feline herpes virus; AT-007 for the treatment of cats infected with feline immunodeficiency virus; AT-008, a small molecule for the treatment of canine lymphoma; AT-009, a caninized MAB used as an aid in the treatment of canine mast cell tumors; AT-010, a caninized MAB used as an aid for the treatment of atopic dermatitis in dogs; AT-011 to treat parvovirus in dogs; and AT-012 for treatment of feline calicivirus in cats. In addition, the company develops AT-015, a felinized MAB intended as an aid in the treatment of cat lymphoma; AT-016 that provides long-term relief of pain and disability caused by osteoarthritis through regeneration of joint damage; AT-017, a lymphoma immunotherapy for dog lymphoma; and AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Kansas City, Kansas.

49 Employees
Last Reported Date: 03/16/15
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer and Treasurer
Total Annual Compensation: $350.0K
Chief Development Officer
Total Annual Compensation: $302.5K
Chief Commercial Officer
Total Annual Compensation: $302.5K
Chief Scientific Officer
Total Annual Compensation: $321.9K
Compensation as of Fiscal Year 2014.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Aratana Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $156,000 against $176,000 a year ago. Loss from operations was $10,863,000 against $9,222,000 a year ago. Loss before income taxes was $9,045,000 against $9,779,000 a year ago. Net loss and comprehensive loss was $8,774,000 or $0.26 per basic and diluted share against $9,152,000 or $0.34 per basic and diluted per share a year ago.

Traverse Biosciences Reaches $250,000 Cooperative Research and Development Agreement with Aratana Therapeutics Inc

Traverse Biosciences has reached a $250,000 cooperative research and development agreement with Aratana Therapeutics Inc. to advance the development of TRB-N0224 for the treatment and control of periodontal disease in companion animals, including dogs and cats. Traverse Biosciences has also granted Aratana an exclusive option to sublicense TRB-N0224 for the treatment and control of periodontal disease in companion animals, inclusive of a binding term sheet governing the potential sublicense agreement.

Aratana Therapeutics, Inc. to Report Q1, 2015 Results on May 08, 2015

Aratana Therapeutics, Inc. announced that they will report Q1, 2015 results at 9:31 PM, GMT Standard Time on May 08, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $13.51 USD +0.03

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.81 USD -0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 617.0x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 492.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at